Shamsollahi H, Younesian S, Nikfarjam A, Nasiri Z, Yunesian M
Heliyon. 2025; 11(4):e42670.
PMID: 40051856
PMC: 11883369.
DOI: 10.1016/j.heliyon.2025.e42670.
Li J, Peng W, Zhang Y, Liu S, Han M, Song R
Infect Drug Resist. 2024; 17:5147-5161.
PMID: 39600325
PMC: 11588667.
DOI: 10.2147/IDR.S483098.
Liao Y, Su J, Zhao J, Qin Z, Zhang Z, Gao W
Front Immunol. 2024; 15:1359380.
PMID: 38881892
PMC: 11176464.
DOI: 10.3389/fimmu.2024.1359380.
Rivera-Perez D, Mendez C, Diethelm-Varela B, Melo-Gonzalez F, Vazquez Y, Meng X
Front Immunol. 2024; 15:1372193.
PMID: 38812507
PMC: 11133585.
DOI: 10.3389/fimmu.2024.1372193.
Sezer Z, Pavel S, Inal A, Yetiskin H, Kaplan B, Uygut M
Vaccines (Basel). 2024; 12(2).
PMID: 38400124
PMC: 10893411.
DOI: 10.3390/vaccines12020140.
Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment.
Holt R, Cockram C, Ma R, Luk A
Diabetologia. 2024; 67(7):1168-1180.
PMID: 38374451
PMC: 11153295.
DOI: 10.1007/s00125-024-06102-x.
Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study).
Molnar G, Voko Z, Suto G, Rokszin G, Nagy D, Surjan G
BMJ Open Diabetes Res Care. 2024; 12(1).
PMID: 38267204
PMC: 10823926.
DOI: 10.1136/bmjdrc-2023-003777.
Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.
He X, Liao Y, Liang Y, Yu J, Gao W, Wan J
Front Immunol. 2024; 14:1290279.
PMID: 38259438
PMC: 10800792.
DOI: 10.3389/fimmu.2023.1290279.
Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak.
Ye W, Li K, Zhao Z, Wu S, Qu H, Guo Y
Front Public Health. 2024; 11:1269194.
PMID: 38162626
PMC: 10757624.
DOI: 10.3389/fpubh.2023.1269194.
Effect of SARS-CoV-2 Infection and BNT162b2 Vaccination on the mRNA Expression of Genes Associated with Angiogenesis.
Wigner-Jeziorska P, Janik-Karpinska E, Niwald M, Saluk J, Miller E
Int J Mol Sci. 2023; 24(22).
PMID: 38003287
PMC: 10671623.
DOI: 10.3390/ijms242216094.
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
He X, Zeng B, Wang Y, Pang Y, Zhang M, Hu T
Front Immunol. 2023; 14:1257360.
PMID: 37915583
PMC: 10616523.
DOI: 10.3389/fimmu.2023.1257360.
Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study.
Wan E, Mok A, Yan V, Chan C, Wang B, Lai F
Cell Rep Med. 2023; 4(10):101195.
PMID: 37716352
PMC: 10591029.
DOI: 10.1016/j.xcrm.2023.101195.
Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review.
He Y, Ouyang J, Hu X, Wu N, Jiang Z, Bian N
World J Diabetes. 2023; 14(6):892-918.
PMID: 37383586
PMC: 10294060.
DOI: 10.4239/wjd.v14.i6.892.
The effectiveness of COVID-19 vaccination against all-cause mortality in patients with type 2 diabetes mellitus: The observation during the initial period of the cancellation of the "Dynamic Zero Policy" in mainland China.
Liu S, Jiang C, Liu Y, Zhang Y, Qiu X, Luo J
Diabetes Res Clin Pract. 2023; 200:110694.
PMID: 37164159
PMC: 10165863.
DOI: 10.1016/j.diabres.2023.110694.
Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C, Wei Y, Yan V, Ye X, Kang W, Yiu H
Lancet Psychiatry. 2023; 10(6):403-413.
PMID: 37141907
PMC: 10191606.
DOI: 10.1016/S2215-0366(23)00111-6.
Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
Xu S, Li J, Wang H, Wang F, Yin Z, Wang Z
BMC Med. 2023; 21(1):160.
PMID: 37106390
PMC: 10134725.
DOI: 10.1186/s12916-023-02861-3.
Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 - China, 2020-2021.
Chen X, Bai X, Chen X, Zheng N, Yang J, Zhang J
China CDC Wkly. 2023; 5(5):103-107.
PMID: 37006710
PMC: 10061772.
DOI: 10.46234/ccdcw2023.019.
Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study.
Tang L, Wang F, Rodewald L, Wang X, Liu S, Liu Q
J Infect Dis. 2023; 228(3):261-269.
PMID: 37005365
PMC: 10420401.
DOI: 10.1093/infdis/jiad090.
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5.
Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P
Vaccines (Basel). 2023; 11(3).
PMID: 36992154
PMC: 10053821.
DOI: 10.3390/vaccines11030570.
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
Wan E, Yan V, Mok A, Wang B, Xu W, Cheng F
Ann Intern Med. 2023; 176(4):505-514.
PMID: 36913693
PMC: 10052319.
DOI: 10.7326/M22-3057.
